GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.

This new article publication from Acta Pharmaceutica Sinica B, discusses how SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts.

Interstitial lung abnormalities (ILAs) are parenchymal lung changes found on high-resolution CT. In routine use of high-resolution CT, non-specific findings are frequently reported, which has prompted ...

Of 14 metabolites identified, 2 appeared to have “robust” causal relationships with idiopathic pulmonary fibrosis.

Panelists discuss that improving outcomes for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) requires multifaceted efforts including developing ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...

The 2014 publication of the ASCEND1 and INPULSIS2 trials and subsequent regulatory approvals of pirfenidone and nintedanib, respectively, represented a watershed moment in the treatment of patients ...

Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

Background: Idiopathic pulmonary fibrosis (IPF) and sarcoidosis are common diagnoses in patients attending chest clinics, but little is known about the epidemiology of these diseases. We used data ...

Background Previous studies have shown that the incidence of idiopathic pulmonary fibrosis (IPF) is rising in the UK and USA. Death registrations and primary care data were used to determine the ...

A basic review of the anatomy, physiology and personal protective equipment related to the respiratory system.

Nerandomilast significantly reduces the decline in forced vital capacity in adults with progressive pulmonary fibrosis over 52 weeks, thereby slowing the progression of the condition.